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1. Introduction 
The hypothalamic tetradecapeptide somatostatin 
[ 11, in addition to its growth hormone release inhibit- 
ing activity, lowers the basal levels of insulin and glu- 
cagon [2,3] and also suppresses the arginine-stimulated 
rise of these pancreatic hormones in man [4]. Unger 
et al. [ 51 have suggested that excessive release of glu- 
cagon either in basal or stimulated state may contrib- 
ute to diabetic hyperglycemia. 
Somatostatin, soon after its discovery, was consid- 
ered as a potential agent for the control of diabetes 
[6]. It became vident, however, that somatostatin 
would have limited use in clinical situations, due to a 
short, < 10 min, biological half-life [7] coupled with 
a diabetogenic activity resulting from the inhibition 
of the insulin secretion [8]. Analogs of somatostatin 
which would preferentially suppress glucagon without 
substantially affecting insulin and at the same time 
possess prolonged activity could be the answer to the 
above disadvantages of somatostatin. An analog, 
D-Trps-D-Cys’4-somatostatin, which shows relative 
specificity for the suppression of growth hormone 
and glucagon has been synthesized [9,10]. However, 
this analog does not show any long lasting activity 
for lowering growth hormone or glucagon [ 111. 
We report here the synthesis and selective inhibi- 
tory activity towards growth hormone and glucagon 
of an analog of somatostatin [des-Ala1,Gly2]His4’5-D- 
Trp’-somatostatin, Wy-41,747, endowed with con- 
siderable prolongation of activity against these hor- 
mones. 
2. Experimental 
The dodecapeptide [des-Ala’,Gly2]-His4~5-somato- 
statin, Wy41,747, was synthesized by the solid phase 
peptide synthesis methodology [ 121. The peptidoresin, 
Boc-Cys(SMBzl)-His(CBZ)-His(CBZ)-Phe-Phe- 
D-Trp-Lys(ClCBZ)-Phe-Thr(Bzl)-Ser(Bzl)- 
Cys(SMBz I)-Bz 1 was treated with anhydrous HF in 
the presence of anisole and the disulfhydryl compound 
was oxidized by air to afford the cyclic disulfide. 
The crude dodecapeptide isulfide was purified by 
gel filtration through Sephadex G-25 followed by 
partition chromatography through Sephadex G-25 
with the biphasic system, n-butanol-water-acetic 
acid, 4:5: 1, v/v/v. Amino acid analysis, Thr(2) 1.94, 
Ser(1) 0.89, Phe(3) 3, Lys(1) 1 .Ol, His(2) 1.88, 
7 ‘i H-Cys-His-His-Phe-Phe-D-Trp-Lys-Thr-Phe-Th-Ser-Cys-OH 
[des-Ala’,Gly2]-His4y5-D-Trp6-somatostatin, Wy41,747 
ElsevierlNorth-Holkmd Biomedical F?ess 153 
Volume 92, number 2 FEBSLETTERS August 1978 
Table 1 
Effects of Wy41,747 on suppression of growth hormone, insulin and 
glucagon at 15 min in rats 
Peptide Dose 
@g/kg) 
Plasma hormone levels (M f SEMI 
Glucagon Insulin Growth hormone 
@g/ml) gcD/mD (nglmll 
Exp. 
None - 33+- 4 256* 18 142 f 20 A 
WY41,747 500 2i 2a 124 f 28a 41~ 6a 
None - 69t 13 278* 32 163 f 29 B 
WY41,747 100 20* 8a 202* 49 20+ 8a 
None _ 87* 10 699 * 201 333 * 38 C 
wy41,747 20 35 f 4a 569 i: 14 138 * 34a 
wy41,747 5 70* 9 559 f 131 188 f 34b 
a P < 0.01 
b P < 0.05 by analysis of variance 
Trp( 1) 0.82, Cys(2) 1.86. Thin-layer chromatography, 
cellulose precoated glass plates (Analtech) RF (n-buta- 
nol-water-acetic acid, 4:l: 1) 0.38, RF (n-butanol- 
water-acetic acid-pyridine, 30:24:6:20) 0.69. 
The hormone inhibiting profile at 15 min after 
subcutaneous injection at various doses of Wy-41,747, 
was measured by suppression of plasma growth hor- 
mone (GH) insulin (INS) and glucagon (GLUN) in 
arginine-stimulated rats anesthetized with nembutal 
as in [ 151. The duration of action of Wy4 1,747 in 
suppressing embutal stimulated growth hormone 
release was determined as in [ 161. 
3. Results 
The favorable specificity for glucagon suppression 
by Wy41,747 can be seen in table 1. The analog 
suppresses growth hormone at doses as low as 5 pg/kg 
and glucagon at a dose of 20 E.cg/kg, while insulin 
levels are lowered significantly by Wy41,747 only at 
a dose of 500 Mg/kg. A comparison between somato- 
statin and Wy41,747 is presented in table 2, which 
shows that Wy4 1,747 is more potent toward gluca- 
gon suppression and less potent toward growth hor- 
mone and insulin lowering. 
Duration of activity of Wy41,747 for growth 
hormone suppression is presented in table 3. A sus- 
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Table 2 
Comparison of minimal effective doses @g/kg) between 
somatostatin and Wy-4 1,747 
Somatostatin wy41,747 
Glucagon 50-100 5- 20 
Insulin 100-200 100-500 
GH 5- 10 5- 20 
pension of Wy41,747 in saline will lower signifi- 
cantly GH levels in rats at a dose of 1 mg/kg, sub- , 
cutaneously, for up to 2 h, while the same dose, 
1 mg/kg, suspended in 80% polyethyleneglycol400 
solution will effectively lower GH for 4 h. Although 
Wy41,747 did not lower glucagon for prolonged 
periods in the model described above, it did lower 
both glucagon and glucose in fasted streptozotocin 
diabetic dogs for 4 h at a dose of 0.5 mg/kg [ 171. 
All of these results characterize Wy41,747 as an 
ideal agent in the treatment of diabetes. 
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Table 3 
Duration of plasma growth hormone suppression in rats 
Peptide Dose N Time (h) Plasma growth hormone 
@g/kg) after (ng/ml) M f SEM 
injection 
Saline 
wy41,747 
Saline 
wy41,747 
Saline 
wy41,747 
80% PEG400 
Wy-4 1,747 in 
80% PEG400 
80% PEG400 
wy41,747 in 
80% PEG4 00 
- 10 2 118*20 
1000 9 2 36 f 6a 
- 10 2 229 f 37 
500 9 2 48 i 16a 
- 9 4 115 f 23 
1000 10 4 62+- 13 
10 4 205 ?; 24 
1000 10 4 100 f 12a 
- 10 5 
lob0 8 5 
186? 200 
161 f 21 
ap < 0.01 
N, number of animals per group 
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